pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

AMGEN

USupdated 5mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Unknown: 1
1Unknown
drug
PROCRIT

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)recruitingn=750
  • phase1Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Canceractive not recruitingn=60
  • phase3Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweightrecruitingn=230
  • phase4EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarctionactive not recruitingn=6,019
  • phase1Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)active not recruitingn=269
  • phase3A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritisrecruitingn=48
  • phase1Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)recruitingn=50
  • phase3Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesityrecruitingn=5,056
🐶 Hiring Signal
No open roles indexed yet — view AMGEN jobs →

News

  • AstraZeneca, Calidi, Tempest make significant workforce cuts
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 17h ago
  • Aclaris drops TSLP program from pipeline after flunking phase 2 eczema test
    A phase 2 study of Aclaris Therapeutics’ bosakitug in atopic dermatitis has missed its primary endpoint, adding to the setbacks anti-TSLP antibodies have encountered in the indication.
    fiercebiotech · 1d ago
  • Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’
    Windward Bio’s IPO has blown to exactly the spot the Swiss biotech had been aiming for, bringing in $225 million to fund a pair of respiratory drugs licensed from China.
    fiercebiotech · 4d ago
  • Windward prices $175M IPO to advance China-licensed lung drugs
    The Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.
    biopharma_dive · 4d ago
  • 10 companies hiring in New Jersey
    Looking for a biopharma job in New Jersey? Jobs on BioSpace increased year over year in October, and there are hundreds of open positions posted now.
    biospace · 5d ago
  • Amgen builds Sjögren’s case with detailed phase 3 data ahead of Novartis showdown
    Amgen has shared more data from a phase 3 Sjögren’s disease trial that dazzled analysts, digging into the details that could shape its showdown with Novartis.
    fiercebiotech · 6d ago
  • AbCellera becomes latest biotech to abandon dream of developing OX40 drug
    AbCellera has become the latest drug developer to abandon its attempts to crack the OX40 code.
    fiercebiotech · 7d ago
  • BioSpace 2027 Best Places to Work shines light on most admired employers
    The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
    biospace · 7d ago
  • Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
    Full data from the Phase 3 HORIZON trial of Novartis' pelacarsen failed to show any apparent benefit, leading analysts to further reduce the odds of success for Lp(a)-lowering competitors such as A…
    biospace · 7d ago
  • STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and more
    Novartis is largely abandoning a drug once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and deaths
    stat · 7d ago
view all news mentions →
identifiers
country
US
source
openfda_drugsfda
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?